1-20 of 29
Charlotte Kopitz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 4584: Novel YAP1/TAZ pathway inhibitors identified through phenotypic screening with potent anti-tumor activity via blockade of GGTase-I and Rho-GTPase signaling

Keith Graham, Philip Lienau, Benjamin Bader, Stefan Prechtl, Jan Naujoks, Ralf Lesche, Barbara Nicke, Wilhelm Bone, Sven Golfier, Krzysztof Brzezinka, Stefan Kaulfuss, Charlotte Kopitz, Holger Steuber, Nico Braeuer, Katrin Nowak-Reppel, Carlo Stresemann, Patrick Steigemann, Julia Kuehnlenz, Lisette Potze, Francesca Zanconato, Anna Montebaur, Sabine Pilari, Sikander Hayat, Atanas Kamburov, Andreas Steffen, Andreas Schlicker, Philipp Buchgraber, Nuria Aiguabella Font, Tobias Heinrich, Lara Kuhnke, Annette O. Walter, Simona Blotta, Matthias Ocker, Ashley Lakner, Dominik Mumberg, Knut Eis, Stefano Piccolo, Martin Lange
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4584.
https://doi.org/10.1158/1538-7445.AM2024-4584
Published: 22 March 2024
View article titled, Abstract 4584: Novel YAP1/TAZ pathway inhibitors identified through phenotypic screening with potent anti-tumor activity via blockade of GGTase-I and Rho-GTPase signaling
Journal Articles

Abstract 6089: Identification of novel YAP/TAZ pathway regulators in the triple-negative breast cancer cell line MDA-MB231 using single-cell CRISPR screening

Mareike Berlak, Zuzanna Makowska, Filippos Klironomos, Julia Kuehnlenz, Atanas Kamburov, Andreas Steffen, Martin Lange, Barbara Nicke, Ralf Lesche, Peter Staller, Charlotte Kopitz, Jan Naujoks
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 6089.
https://doi.org/10.1158/1538-7445.AM2023-6089
Published: 04 April 2023
View article titled, Abstract 6089: Identification of novel YAP/TAZ pathway regulators in the triple-negative breast cancer cell line MDA-MB231 using single-cell CRISPR screening
Journal Articles

Abstract ND04: BAY 2666605: The first PDE3A-SLFN12 complex inducer for cancer therapy

Stefan Gradl, Sooncheol Lee, Martin Lange, Xiaoyun Wu, Silvia Goldoni, Timothy Lewis, Charlotte Kopitz, Colin Garvie, Philip Lienau, Stephanie Hoyt, Henrik Seidel, Stephan Kaulfuss, Manuel Ellermann, Luc de Waal, Adrian Tersteegen, Sven Golfier, Detlev Suelzle, Christa Hegele-Hartung, James Carr, Frederick Brookfield, Michael Bruening, Melanie Berthold, Thibaud Jourdan, Monica Schenone, Galen Gao, Joseph McGaunn, Antje Wengner, Elisa Aquilanti, Franziska Siegel, Marine Garrido, Annette Walter, Isabelle Genvresse, Andrew Cherniack, Stuart Schreiber, Knut Eis, Ashley Eheim, Matthew Meyerson, Heidi Greulich
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): ND04.
https://doi.org/10.1158/1538-7445.AM2022-ND04
Published: 15 June 2022
View article titled, Abstract ND04: BAY 2666605: The first PDE3A-SLFN12 complex inducer for cancer therapy
Journal Articles

Abstract 2663: Preclinical profiling of BAY 2666605: The first PDE3A-SLFN12 complex inducer for cancer therapy

Silvia Goldoni, Martin Lange, Charlotte Kopitz, Stefan Kaulfuss, Sven Golfier, Adrian Tersteegen, Stefanie Bunse, Melanie Berthold, Thibaud Jordan, Philip Lienau, Franziska Siegel, Annette Walter, Henrik Seidel, Elisa Aquilanti, Andrew Baker, Xiaoyun Wu, Sooncheol Lee, Stefan Gradl, Emmanuelle di Tomaso, Matthew Meyerson, Knut Eis, Ashley Eheim, Heidi Greulich
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2663.
https://doi.org/10.1158/1538-7445.AM2022-2663
Published: 15 June 2022
View article titled, Abstract 2663: Preclinical profiling of BAY 2666605: The first PDE3A-SLFN12 complex inducer for cancer therapy
Journal Articles

Abstract 1314: A novel small molecule drug conjugate -avb3 integrin antagonist linked to a cytotoxic camptothecin derivative- for the treatment of multiple cancer types

Hans-Georg Lerchen, Beatrix Stelte-Ludwig, Charlotte Kopitz, Melanie Heroult, Dmitry Zubov, Joerg Willuda, Thomas Schlange, Antje Kahnert, Raquel Izumi, Ahmed Hamdy
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1314.
https://doi.org/10.1158/1538-7445.AM2021-1314
Published: 01 July 2021
View article titled, Abstract 1314: A novel small molecule drug conjugate -avb3 integrin antagonist linked to a cytotoxic camptothecin derivative- for the treatment of multiple cancer types
Journal Articles

Abstract 1780: Anetumab ravtansine has single-agent activity in mesothelin-expressing human ovarian cancer models and potentiates the activity of chemotherapeutics and targeted agents

Christoph A. Schatz, Maria Quanz, Urs B. Hagemann, Sabine Zitzmann-Kolbe, Beatrix Stelte-Ludwig, Sven Golfier, Charlotte Kopitz, Cem Elbi, Karl Ziegelbauer, Dominik Mumberg
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1780.
https://doi.org/10.1158/1538-7445.AM2018-1780
Published: 01 July 2018
View article titled, Abstract 1780: Anetumab ravtansine has single-agent activity in mesothelin-expressing human ovarian cancer models and potentiates the activity of chemotherapeutics and targeted agents
Journal Articles

Abstract 5880: Small-molecule modulators of PDE3/SLFN12 to kill cancer cells

Timothy A. Lewis, Luc de Waal, Xiaoyun Wu, Manuel Ellerman, Charlotte Kopitz, Antje Wengner, Knut Eis, Martin Lange, Adrian Tersteegen, Philip Lienau, Heidi Greulich, Matthew Meyerson
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 5880.
https://doi.org/10.1158/1538-7445.AM2018-5880
Published: 01 July 2018
View article titled, Abstract 5880: Small-molecule modulators of PDE3/SLFN12 to kill cancer cells
Journal Articles

Preclinical Efficacy of the Auristatin-Based Antibody–Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors

Anette Sommer, Charlotte Kopitz, Christoph A. Schatz, Carl F. Nising, Christoph Mahlert, Hans-Georg Lerchen, Beatrix Stelte-Ludwig, Stefanie Hammer, Simone Greven, Joachim Schuhmacher, Manuela Braun, Ruprecht Zierz, Sabine Wittemer-Rump, Axel Harrenga, Frank Dittmer, Frank Reetz, Heiner Apeler, Rolf Jautelat, Hung Huynh, Karl Ziegelbauer, Bertolt Kreft
Journal: Cancer Research
Series: Author Choice
Cancer Res (2016) 76 (21): 6331–6339.
https://doi.org/10.1158/0008-5472.CAN-16-0180
Published: 31 October 2016
View article titled, Preclinical Efficacy of the Auristatin-Based Antibody–Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors
Open the PDF for Preclinical Efficacy of the Auristatin-Based Antibody–Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Abstract 4746: Pharmacological characterization of BAY-876, a novel highly selective inhibitor of glucose transporter (GLUT)-1 in vitro and in vivo

Charlotte Kopitz, Luisella Toschi, Carolyn Algire, Mélanie Héroult, Anna-Lena Frisk, Kirstin Meyer, Arndt Schmitz, Eleni Lagkadinou, Heike Petrul, Iring Heisler, Roland Neuhaus, Bernd Buchmann, Herbert Himmel, Marcus Bauser, Andrea Haegebarth, Karl Ziegelbauer
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 4746.
https://doi.org/10.1158/1538-7445.AM2016-4746
Published: 15 July 2016
View article titled, Abstract 4746: Pharmacological characterization of BAY-876, a novel highly selective inhibitor of glucose transporter (GLUT)-1 in vitro and in vivo
Journal Articles

Abstract 1683: Pharmacokinetic/pharmacodynamic (PK/PD) and toxicokinetic/toxicodynamic (TK/TD) modeling of preclinical data of FGFR2-ADC (BAY 1187982) to guide dosing in phase 1

Sabine Wittemer-Rump, Anette Sommer, Charlotte Kopitz, Hung Huynh, Christoph Schatz, Ruprecht Zierz, Manuela Braun, Kirstin Meyer, Dirk Laurent, Jörg Lippert, Klaas Prins
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 1683.
https://doi.org/10.1158/1538-7445.AM2015-1683
Published: 01 August 2015
View article titled, Abstract 1683: Pharmacokinetic/pharmacodynamic (PK/PD) and toxicokinetic/toxicodynamic (TK/TD) modeling of preclinical data of FGFR2-ADC (BAY 1187982) to guide dosing in phase 1
Journal Articles

Abstract 665: Inhibition of mitochondrial complex I enhances the therapeutic benefit of BRAF inhibition in mutant melanoma cell lines

Laura Schoeckel, Katharina Bitschar, Mélanie Héroult, Charlotte Kopitz, Andrea Hägebarth
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 665.
https://doi.org/10.1158/1538-7445.AM2015-665
Published: 01 August 2015
View article titled, Abstract 665: Inhibition of mitochondrial complex I enhances the therapeutic benefit of BRAF inhibition in mutant melanoma cell lines
Journal Articles

Abstract 772: Anti-tumor efficacy of the selective pan-FGFR Inhibitor BAY 1163877 in preclinical squamous cell carcinoma models of different origin

Mélanie Héroult, Matthias Ocker, Charlotte Kopitz, Dieter Zopf, Andrea Hägebarth, Karl Ziegelbauer, Stuart Ince, Peter Ellinghaus
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 772.
https://doi.org/10.1158/1538-7445.AM2015-772
Published: 01 August 2015
View article titled, Abstract 772: Anti-tumor efficacy of the selective pan-FGFR Inhibitor BAY 1163877 in preclinical squamous cell carcinoma models of different origin
Journal Articles

Abstract 1684: Preclinical anti-tumor efficacy of FGFR2-ADC BAY 1187982 in patient-derived gastric, breast and ovarian cancer models

Anette Sommer, Charlotte Kopitz, Christoph Schatz, Ruprecht Zierz, Joachim Schuhmacher, Sabine Wittemer-Rump, Klaas Prins, Manuela Braun, Frank Reetz, Bertolt Kreft, Hung T. Huynh, Karl Ziegelbauer
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 1684.
https://doi.org/10.1158/1538-7445.AM2015-1684
Published: 01 August 2015
View article titled, Abstract 1684: Preclinical anti-tumor efficacy of FGFR2-ADC BAY 1187982 in patient-derived gastric, breast and ovarian cancer models
Journal Articles

Abstract DDT02-01: In vitro and in vivo characterization of a novel anti-fibroblast growth factor receptor (FGFR) 2 antibody (BAY 1179470) for the treatment of gastric cancer

Charlotte Kopitz, Anette Sommer, Stefanie Hammer, Axel Harrenga, Beatrix Stelte-Ludwig, Frank Dittmer, Frank Reetz, Ekkehard May, Ruprecht Zierz, Sabine Wittemer-Rump, Christoph Schatz, H. T. Huynh, Karl Ziegelbauer, Bertolt Kreft
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): DDT02-01.
https://doi.org/10.1158/1538-7445.AM2014-DDT02-01
Published: 01 October 2014
View article titled, Abstract DDT02-01: In vitro and in vivo characterization of a novel anti-fibroblast growth factor receptor (FGFR) 2 antibody (BAY 1179470) for the treatment of gastric cancer
Journal Articles

Abstract 5445: Preclinical anti-tumor efficacy of an anti-C4.4a (LYPD3) antibody drug conjugate for the treatment of lung squamous cell carcinoma

Joerg Willuda, Lars Linden, Hans-Georg Lerchen, Charlotte Kopitz, Sven Golfier, Ute Bach, Joachim Schumacher, Beatrix Stelte-Ludwig, Oliver Von Ahsen, Claudia Schneider, Frank Dittmer, Rudolf Beier, Sherif El-Sheik, Jan Tebbe, Gabriele Leder, Heiner Apeler, Rolf Jautelat, Bertolt Kreft, Karl Ziegelbauer
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 5445.
https://doi.org/10.1158/1538-7445.AM2014-5445
Published: 01 October 2014
View article titled, Abstract 5445: Preclinical anti-tumor efficacy of an anti-C4.4a (LYPD3) antibody drug conjugate for the treatment of lung squamous cell carcinoma
Journal Articles

Abstract 672: Pharmacokinetic and pharmacodynamic (PK/PD) modeling of preclinical data of a novel anti-fibroblast growth factor receptor 2(FGFR2) antibody (BAY 1179470) to guide dosing in Phase 1

Sabine Wittemer-Rump, Charlotte Kopitz, Hung Huynh, Lars Lindbom, Bernhard Beckermann, Motonobu Osada, Dirk Laurent, Jörg Lippert
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 672.
https://doi.org/10.1158/1538-7445.AM2014-672
Published: 01 October 2014
View article titled, Abstract 672: Pharmacokinetic and pharmacodynamic (PK/PD) modeling of preclinical data of a novel anti-fibroblast growth factor receptor 2(FGFR2) antibody (BAY 1179470) to guide dosing in Phase 1
Journal Articles

Abstract 4766: Pharmacodynamic and stratification biomarker for the anti-FGFR2 antibody (BAY1179470) and the FGFR2-ADC

Christoph A. Schatz, Charlotte Kopitz, Sabine Wittemer-Rump, Anette Sommer, Lars Lindbom, Motonobu Osada, Hiroshi Yamanouchi, Hung Huynh, Thomas Krahn, Khusru Asadullah
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 4766.
https://doi.org/10.1158/1538-7445.AM2014-4766
Published: 01 October 2014
View article titled, Abstract 4766: Pharmacodynamic and stratification biomarker for the anti-FGFR2 antibody (BAY1179470) and the FGFR2-ADC
Journal Articles

Abstract 2726: Efficacy and candidate biomarker evaluation for the anti-mesothelin antibody drug conjugate (ADC) BAY 94-9343, mesothelin-ADC in mesothelin-positive preclinical xenograft models

Christoph A. Schatz, Sven Golfier, Claudia Scheider, Charlotte Kopitz, Kerstin Berhörster, David Henderson, Arndt Schmitz, Thomas Krahn, Bertolt Kreft, Karl Ziegelbauer
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 2726.
https://doi.org/10.1158/1538-7445.AM2012-2726
Published: 15 April 2012
View article titled, Abstract 2726: Efficacy and candidate biomarker evaluation for the anti-mesothelin antibody drug conjugate (ADC) BAY 94-9343, mesothelin-ADC in mesothelin-positive preclinical xenograft models
Journal Articles

Abstract 1754: Identification of BAY 94-9343, a mesothelin antibody-drug conjugate (ADC): Characterization and anti-tumor activity in mesothelin-positive preclinical tumor models

Sven Golfier, Antje Kahnert, Iring Heisler, Charlotte Kopitz, Kerstin Berhörster, Beatrix Stelte-Ludwig, Anke Mayer-Bartschmid, Sandra Bruder, Lars Linden, Axel Harrenga, Christoph Schatz, Bertolt Kreft, Beate Müller-Tiemann, Karl Ziegelbauer
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 1754.
https://doi.org/10.1158/1538-7445.AM2011-1754
Published: 15 April 2011
View article titled, Abstract 1754: Identification of BAY 94-9343, a mesothelin antibody-drug conjugate (ADC): Characterization and anti-tumor activity in mesothelin-positive preclinical tumor models
Journal Articles

Abstract 3614: In vivo efficacy of the carbonic anhydrase IX (CA9)-targeted antibody-drug conjugate BAY 79-4620 is superior to that of microtubule inhibitors in preclinical models of NSCLC, gastric and colorectal cancer

Heike Petrul, Charlotte Kopitz, Christoph Schatz, Rudolf Beier, Miriam Zatovicova, Silvia Pastorekova, Bertolt Kreft, Karl Ziegelbauer
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 3614.
https://doi.org/10.1158/1538-7445.AM2011-3614
Published: 15 April 2011
View article titled, Abstract 3614: In vivo efficacy of the carbonic anhydrase IX (CA9)-targeted antibody-drug conjugate BAY 79-4620 is superior to that of microtubule inhibitors in preclinical models of NSCLC, gastric and colorectal cancer